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Retinal ageing results in chronic inﬂammation, extracellular deposition, including that of amyloid beta
(Ab) and declining visual function. In humans this can progress into age-related macular degeneration
(AMD), which is without cure. Therapeutic approaches have focused on systemic immunotherapies
without clinical resolution. Here, we show using aged mice that 2-Hydroxypropyl-b-cyclodextrin, a sugar
molecule given as eye drops over 3 months results in signiﬁcant reductions in Ab by 65% and inﬂam-
mation by 75% in the aged mouse retina. It also elevates retinal pigment epithelium speciﬁc protein 65
(RPE65), a key molecule in the visual cycle, in aged retina. These changes are accompanied by a sig-
niﬁcant improvement in retinal function measured physiologically. 2-Hydroxypropyl-b-cyclodextrin is as
effective in reducing Ab and inﬂammation in the complement factor H knockout (Cfh/) mouse that
shows advanced ageing and has been proposed as an AMD model. b-cyclodextrin is economic, safe and
may provide an efﬁcient route to reducing the impact of retinal ageing.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Ageing is associated with cellular decline which is partly linked
to metabolic rate. The outer retina has the highest metabolic de-
mand in the body required to maintain the oxygen demanding
photoreceptor population (Linsenmeier and Padnick-Silver, 2000).
Here with age there is progressive accumulation of extracellular
material including neurotoxic amyloid beta (Ab) (Isas et al., 2010),
lipids (Curcio et al., 2005a,Curcio et al., 2005b,Wang et al., 2010)
and proteins that are inﬂammatory such as complement (Hageman
et al., 2001). These accumulate on Bruch's membrane (BM)
restricting the exchange of metabolic nutrients between the outer
retina and its blood supply. In mice these deposits are relatively
linear along BM. In humans, deposits are focal and are called dru-
sen. These are a key risk factor for age-related macular degenera-
tion (AMD) when they accumulate in the central retina. With
progressive deposition and inﬂammation 30% of the photoreceptor
population is lost in both humans and rodents in normal ageing
(Cunea and Jeffery, 2007,Curcio et al., 1993).
In humans, retinal ageing can develop into AMD wheregy, UCL, 11-43 Bath Street,
r Ltd. This is an open access articleprogressive inﬂammation and deposition result in central retina
atrophy. Mice lack this area of specialisation and do not develop
retinal atrophy but do suffer from similar deposition, inﬂammation
and cell loss across the retina. AMD is the leading cause of blindness
in those over 65 years in the West and is growing rapidly as pop-
ulations age (Klein et al., 1997,Klein et al., 2004). In 50% of cases it is
linked to immune vulnerability being associated with poly-
morphisms of complement genes (Edwards et al., 2005,Haines
et al., 2005). Currently, there is no cure for this neurodegenera-
tive disease, although systemic immunotherapeutic approaches
have tried to reduce retinal Ab load (Catchpole et al., 2013,DeMattos
et al., 2001,Ding et al., 2011; Salloway et al., 2014). However, topical
drug administration has largely been ignored as it was seen as
unlikely to be effective due to drug dilution before it reached the
retina. This assumes that drugs would have to pass through the
anterior eye and vitreous before entering the retina. However,
penetration of the drug may be obtained via the conjunctiva and
sclera into the retina (Sigurdsson et al., 2007).
Cyclodextrins (CDs) are a family of cyclic polysaccharide com-
pounds with a hydrophilic shell enclosing a hydrophobic cavity.
This structure allows them to form wateresoluble complexes with
otherwise insoluble hydrophobic compounds. This has led to their
utilisation as carriers to increase the aqueous solubility and sta-
bility of hydrophobic drugs (Loftsson and Duchene, 2007; Stella and
He, 2008). They have undergone extensive safety studies and areunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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He, 2008) for pharmaceutical use and dietary supplements.
Topical administration results in their rapid retinal accumulation,
presumably entering the eye via the conjunctiva (Loftsson et al.,
2008; Sigurdsson et al., 2007).
Recently, CDs systemic delivery has shown efﬁcacy in an Alz-
heimer's mouse model (Yao et al., 2012) reducing the size of Ab
plaques in the brain and upregulating genes associated with
cholesterol transport and Ab clearance. Further, systemic delivery
signiﬁcantly reduces lipofuscin deposits in the retina, which are an
age related lipid rich pigmented deposit that accumulates in the
retinal pigmented epithelium (Nociari et al., 2014). CDs are known
to bind to cholesterol (Irie et al., 1992,Ohtani et al., 1989) and at high
concentrations, they serve as a cholesterol sink. At low concentra-
tions, CDs act as a cholesterol shuttle, transporting it between
membranes (Atger et al., 1997; McCauliff et al., 2011). Hence, they
can clear cholesterol which is known to be deposited on BM and
whose presence has been linked to AMD (Pikuleva and Curcio,
2014).
Here, we ask whether topical CDs delivery has the ability to
erode Ab and reduce inﬂammation in the aged mouse retina and
what impact this has on retinal function. This was based on our
prior observation that CDs had the ability to enter the retina via the
conjunctiva. We explore this in normal aged mice but also ask if it
has similar abilities in terms of Ab and inﬂammation alone in aged
complement factor H mice (Cfh/) that have been proposed as a
murine model of AMD as it shares a genotype with 50% of AMD
patients (Coffey et al., 2007). While there remain signiﬁcant ques-
tions regarding mouse AMD models due to the absence of a mac-
ular, the aged Cfh/ mouse does experience elevated deposition
and inﬂammation and has reduced photoreceptor numbers and
compromised visual function (Hoh Kam et al., 2013).
2. Materials and methods
2.1. Animals
8-9 months old C57BL/6 and 6e7 months old Cfh/mice which
were backcrossed onto C57BL/6 genetic background for more than
10 generations were used. Animals were housed under a 12/12 light
dark cycle with access to food and water ad libitum. All animals
were used with University College London ethics committee
approval that conformed to the United Kingdom Animal License
(Scientiﬁc Procedures) Act 1986 (UK). UK Home Ofﬁce project li-
cense (PPL 70/6571).
2.2. Treatment regime
C57BL/6 mice (n ¼ 10) were treated with 3 ml of 10% 2-
Hydroxypropyl-b-cyclodextrin (b-CD) (Sigma Aldrich, UK) in
phosphate buffered saline (pH 7.4) as eye drops bilaterally 3 times
daily for 3 months. Controls (n ¼ 5) were untreated.
The Cfh/ mice were divided into 3 groups. The ﬁrst (b-CD LT)
was treated with 3 ml of 10% 2-Hydroxypropyl-b-cyclodextrin (b-
CD) (Sigma Aldrich, UK) as above as eye drops 3 times a day for 3
months (n ¼ 10). The second (control) of Cfh/ mice (n ¼ 5) was
left untreated. The third group (b-CD ST) was treated with 3 ml of
10% b-CD (Sigma Aldrich, UK) as above as eye drops 3 times a day
for 3 days per month for 3 months (n ¼ 5).
2.3. Electroretinogram (ERG)
After treatment C57BL/6 animals were given full ﬁeld ﬂash ERG
to assess retinal function in response under scotopic and photopic
conditions similar to Hoh Kam et al. (2013) using the ColorDomeGanzfeld ERG (Diagnosys LLC, Cambridge, UK). Mice were dark-
adapted overnight for scotopic measurements and anaesthetised
with 6% Ketamine, (National Veterinary Services Ltd, UK) 10%
Dormitor, (National Veterinary Services Ltd, UK) and 84% sterile
water at 5ul/g intraperitoneal injection. Pupils were dilated (1%
Tropicamide, MINIMS, Bausch & Lomb, France) prior to recordings.
Ground and reference subdermal electrodes were placed subcuta-
neously near the hindquarter and between the eyes respectively
and the mouse placed on a heated pad (37 C). Recording gold
electrodes were placed on the cornea. ERG was carried out under
scotopic conditions for both eyes simultaneously, with increasing
stimulus strengths using a 6500 K white light at; 3.5  106,
3.5  105, 3.5  104, 0.03, 0.3, 2.8 and 28.1 cd s/m2. After the
scotopic series mice were adapted to a 20 cd/m2 background for
20 min. Then photopic responses to white light ﬂash stimuli of 0.3,
2.8, 28.1 and 84.2 cd s/m2 were recorded with a background light of
20 cd/m2. An average of 20e25 readings were taken for each in-
tensity. Statistical differences between groups were evaluated by
using random ANOVA.
2.4. Immunohistochemistry
After ERGs, C57BL/6 mice were culled by cervical dislocation as
were the Cfh/ mice fromwhich recordings were not undertaken.
Eyes were collected and ﬁxed in 4% paraformaldehyde in phosphate
buffered saline (PBS), pH 7.4, for 1 h, cryopreserved in 30% sucrose
in PBS and embedded in optimum cutting temperature (OCT)
compound (Agar Scientiﬁc Ltd). 10 mm cryosections were thaw-
mounted on a slide and incubated for 1 h at room temperature in
a 5% Normal Donkey serum in 0.3% (v/v) Triton X-100 in PBS, pH 7.4.
This was followed by an overnight incubation with either a mouse
monoclonal antibody to Ab 4G8 (1:100, Covance), a mouse mono-
clonal antibody to RPE65 (1:500, Merck Millipore, UK), both were
conjugated with an Alexa Fluor 568 (Invitrogen, UK), or a rat
monoclonal antibody to complement C3b (C3b) (1:50, Hycult
biotechnology) diluted in 1% Normal Donkey Serum in 0.3% Triton
X-100 in PBS. For the Cfh/ mice, we used a goat polyclonal to
complement C3 (1:500, Cappel MP Biomedicals, Cambridge, UK).
After primary antibody incubation, sections were washed several
times in 0.1M PBS then slides stained for active C3bwere incubated
in a secondary antibody, donkey anti-rat conjugated with Alexa
Fluor 488 (Invitrogen, UK) and for a donkey anti-goat conjugated
with Alexa Fluor 488 (Invitrogen, UK) for C3, made up in 2% Normal
Donkey Serum in 0.3% Triton X-100 in PBS at a dilution of 1:2000
for 1 h at room temperature. Negative controls were undertaken by
omitting the primary antibody. After secondary antibody incuba-
tion, sections were washed and nuclei stained with DAPI. Slides
were thenwashed in 0.1 M PBS followed by washes in Tris buffered
Saline (pH 7.5). Slides were mounted in Vectashield (VECTOR Lab-
oratories) and coverslipped.
For lipid detection retinal sections were stainedwith a saturated
solution (3%) of Sudan Black B in 70% ethanol for 1 h at room
temperature and thenwashed in several changes of distilled water.
Slides were mounted in glycerol and then coverslipped.
2.5. Western blots
Eyes were dissected on ice and the retina and RPE-choroidal
tissues were snap frozen in liquid nitrogen. Protein was then
extracted by homogenising the samples in 2% SDS with protease
inhibitor cocktail (Roche diagnostics), and centrifuged at 13,000g.
The supernatant was transferred to a newmicrocentrifuge tube and
will be used for Western blots of C3 and RPE65. Ab was extracted
from the resultant pellet with 70% formic acid and the mixture was
then centrifuged at 13,000 g. The supernatant was then
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The formic acid in the supernatant was evaporated using a speed-
Vac concentrator (The Eppendorf Vacuum Concentrator Model
5301, Brinkmann) and the protein pellet was reconstituted in 10%
dimethyl sulfoxide in 2 mol/L TriseHCl. Protein concentration was
measured with an absorbance of 595 nm and Bovine Serum Albu-
min was used as a standard protein concentration. Equal amounts
of proteins (50 mg/ml) were separated by a 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and electrophoretically
transferred onto nitrocellulose membranes. The nitrocellulose
membranes were pre-treatedwith 5% non-fat driedmilk in 1M PBS
(pH7.4) for 1 h and incubated overnight at 4 C with either a goat
polyclonal antibody to C3 (1:500, Cappel), a rabbit monoclonal to
RPE65 (1:1000, Abcam), a mouse monoclonal antibody to Ab 4G8
(1:1000, Covance) or a mouse monoclonal to a-tubulin (1:1000,
Millipore) followed by several washes in 0.05% Tween-20 in 1 M
PBS. The membranes were then incubated with the respective
secondary antibodies; rabbit anti-goat HRP conjugated (1:2000,
Dako), goat anti-rabbit HRP conjugated (1: 3000, Dako) and goat
anti-mouse HRP conjugated (1:10,000, Thermo Scientiﬁc) for 1 h.
Immunoreactivities were visualised by exposing x-ray ﬁlms to blots
incubated with ECL reagent (SuperSignal West Dura, Thermo Sci-
entiﬁc). Total protein proﬁle was determined by staining blots with
Ponceau S solution to check the transfer efﬁciency and quantiﬁca-
tion. Protein bands were then photographed and scanned. The
absolute intensity of each band was then measured using Adobe
Photoshop CS5 extended.
2.6. Analysis
2.6.1. Measurement of the expression of Ab, C3b, RPE65 and C3
along the RPE and Bruch's membrane interface by immunostaining
Fluorescence images were taken in JPEG format at 400 using
an Epi-ﬂuorescence bright-ﬁeld microscope. Images were
montaged and the integrated density, which is the product of the
area chosen (in pixels) and the mean grey value (measurement of
the brightness), were recorded using Adobe Photoshop CS5
extended. The lasso tool was used to draw a line all the way around
the RPE and Bruch's membrane interface to measure the amyloid
beta, RPE65, C3 and the C3b expression in this area.
2.6.2. Measurement of the amount of Ab, C3 and RPE65 in Western
blots
Scanned images of the immunoblots were inverted to grayscale
format and the mean gray value was measured for each protein
band by using the lasso tool to draw a line all the way around the
edges of the band using Adobe Photoshop CS5 extended. The ab-
solute intensity was calculated by multiplying the mean gray value
and the pixel value. The protein bands were quantiﬁed and their
ratios to alpha tubulin were calculated and plotted into graphs.
2.6.3. Statistical analysis
A ManneWhitney U test was used to compare groups and a one
way ANOVA with post hoc analysis with Dunn's multiple compar-
ison test was used for the three groups. Data was analysed using
Graph pad Prism, version 5.0 (Graphpad, San Diego, CA).
3. Results
3.1. b-CD signiﬁcantly reduces Ab and inﬂammation and elevates
RPE65 in aged C57BL/6 mice
We administered b-CD as single eye drops for 3 months in old
C57BL/6 mice in which Ab deposition and inﬂammation were
established (Catchpole et al., 2013). All b-CD-treated mice had asigniﬁcant reduction of around 65% in Ab deposition on BM when
immunostained tissue was examined (P < 0.05, Fig. 1A and B)
compared with controls. Further, while Ab deposition was rela-
tively focal on BM in the untreated group, in b-CD-treated mice its
distribution was clearly diffuse, which may be attributable to the
process of clearance (Fig. 1A, arrowheads). Western blot was also
used to quantify Ab deposition in the retina and RPE of both the b-
CD-treated and untreated mice (Fig. 1C). The results showed that b-
CD decreased retinal Ab levels markedly but this was not signiﬁcant
(P > 0.05).
To determine if reductions in pro-inﬂammatory Ab (Johnson
et al., 2002) were associated with a decreased inﬂammation, we
immunostained adjacent section for active complement C3 (C3b)
(Fig. 1C). There was a signiﬁcant decline of around 75% in C3b on
BM in b-CD-treated mice compared with controls (P < 0.05, Fig. 1D
and E). Western blot results showed a decrease in the level of C3 in
the b-CD-treated mice compare to controls, but this did not reach
statistical signiﬁcance (P > 0.05, Fig. 1F). Hence, topical adminis-
tration of b-CD reduced Ab deposition and inﬂammation in the
aged outer retina.
There is evidence from amphibians that b-CD improves the vi-
sual cycle (Johnson et al., 2010), which is an enzyme pathway
where opsin is recycled. This involves the removal of all-trans
retinol, a potentially toxic element whose accumulation results in
vulnerability to light-induced photoreceptor damage. Elevated all-
trans retinol is also linked to Stargardt disease, a rare early onset
form of AMD (K. Haddley, 2011; Moiseyev et al., 2010). In frogs, b-
CD clears all-trans retinol in a dose-dependent manner (Johnson
et al., 2010).
To determine if CDs impact on the visual cycle in aged mice we
immunostained sections for retinal pigment epithelium speciﬁc
protein 65 (RPE65), which is a protein expressed in the retinal
pigment epithelium (RPE) that plays a critical role in recycling vi-
sual pigments. There was an approximate 30% increase in RPE65
expression in b-CD-treated mice compared to controls (P < 0.01,
Fig. 2A and B). Differences were not simply related to intensity of
labelled RPE65, but also to its distribution. In treated animals
expression was continuous along the RPE, but in controls label was
patchy with gaps that implied its expression was low in some RPE
cells.
To further quantify RPE65 in the RPE and retina, Western blot
analysis was undertaken. The results revealed that there is a sig-
niﬁcant increase in the level of RPE65 in the b-CD-treated mice
compare to the untreated (P< 0.05, Fig. 2C). This conﬁrms the result
obtained with immunostaining and shows that b-CD improves the
visual cycle.
Ageing is also associated with an accumulation of retinal lipids
and it has been argued that this may contribute to AMD (Suzuki
et al., 2007; Curcio et al., 2009; Wiegand et al., 1983). Phospho-
lipids are produced in photoreceptors and subsequently deposited
in the RPE as lipofuscin in the daily shedding of outer segments and
their phagocytosis (Bok, 1985) potentially leading to RPE dysfunc-
tion and photoreceptor death (Suzuki et al., 2007). To reveal
phospholipids and lipids, sections from both treated and controls
were stained with Sudan Black B, which is a histochemical lipids
stain (Fig. 2D). It was not possible to assess staining on BM because
melanin obscured the staining patterns. However, staining on outer
segments was clear and there were marked qualitative differences
between b-CD-treated and control mice with reduced staining in
the former group (Fig. 2D).
3.2. b-CD signiﬁcantly improves retinal function in aged C57BL/6
mice
Signiﬁcant reductions in Ab and inﬂammation along with
Fig. 1. b-CD treatment efﬁciently removes Ab and complement C3b along the RPE/BM interface in the C57BL/6 mice. A. Retinal sections from mice of both b-CD-treated and
untreated groups immunostained with a mouse monoclonal Ab 4G8 (red) and the nuclei counterstained with DAPI (blue). Centre panels are close-ups of the RPE/BM interface
showing that the Ab expression in the control group is more focal and punctate (arrowheads). B. b-CD-treated mice have signiﬁcantly reduced Ab deposition along the RPE/BM
interface compared to controls (P < 0.05). C. Graph showing the quantiﬁcation of Ab 4G8 in the retina and RPE. The Western blot results showed that b-CD decrease retinal Ab levels.
D. Retinal sections immunostained with a rat monoclonal antibody to active C3b (green) and counterstained with DAPI (blue). E. Graph showing b-CD-treated mice have signif-
icantly lower C3b expression along the RPE/BM interface (P < 0.05) than controls. F. Graph showing the quantitative measurement of C3 in the retina and RPE. b-CD-treated mice
have less level of inﬂammation compare to controls but this did not reach signiﬁcance (P > 0.05). (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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retinal function. This was measured with scotopic and photopic
ERG recordings. There are marked reductions in the amplitude of
the individual ERG waves with age and pathology (Arden, 2006).
Clear signiﬁcant improvements in amplitudes of the aged ERG
waves of both rod and cone function were found in treated mice
(Fig. 3A and B) but no difference was seen in the latencies (data not
shown). Clear signiﬁcant improvements were marked at higher
luminance where an increase of approximately 28% was shown in
the scotopic a-wave amplitude (P< 0.05, Fig. 3C) at 28.1 cd s/m2 and
25% in the scotopic b-wave amplitude (P < 0.01 at 2.8 and
P < 0.05 at 28.1 cd s/m2, Fig. 3D). A signiﬁcant 20% improvement in
the photopic b-wave was also seen in treated mice at the highest
luminance, 84.2 cd s/m2 (P< 0.05, Fig. 3E). Hence, both the a- and b-
waves under both scotopic and photopic conditions were signiﬁ-
cantly improved in b-CD-treated mice, suggesting that b-CD
treatment improved both rod and cone function and hence
improved visual function over a large dynamic range.3.3. b-CD signiﬁcantly reduces Ab and inﬂammation in the BM of a
murine model of AMD
Having established that b-CD is effective in reducing features of
outer retina ageing we ask two further questions. First, is b-CD also
effective in treating aged Cfh/ mice in terms of Ab and inﬂam-
mation as it is in normal ageing when given the same dosage
patterns? Cfh/ mice suffer from premature retinal Ab and
inﬂammation accumulation (Catchpole et al., 2013) and share a
genotype with 50% of AMD patients (Edwards et al., 2005; Haines
et al., 2005). Second, if so, can this be achieved with a much
lower dosing pattern? Hence, we only dosed at 10% of the level for
the long term treatment in C57BL/6 mice with a total of 27 eye
drops per eye over 3 months.
Fig. 4 shows data from both long term treatment (b-CD LT) in
Cfh/ mice and also short term treatment (b-CD ST) where dosing
was reduced by 90%. In both groups, Ab was signiﬁcantly reduced
on BM compared to controls (Fig. 4A and C). As with the C57BL/6
Fig. 2. b-CD treatment efﬁciently increase RPE65, a visual cycle protein in the aged C57BL/6 mice. A. Retinal sections immunostained with a monoclonal antibody to RPE65 (red).
Nuclei were counterstained with DAPI (blue). RPE65 expression in the RPE is signiﬁcantly higher in the b-CD-treated mice and is continuous compared to controls where the
expression is weaker and there are areas of no staining is seen. B. Differences in RPE65 expression between b-CD-treated and untreated mice were signiﬁcantly different with b-CD-
treated increasing RPE65 expression (P < 0.01). C. Graph showing the quantitative measurement of RPE65 in the RPE and retina. It shows that the level of RPE65 is signiﬁcantly
increase in b-CD-treated mice (P < 0.05). D. Representative micrographs of photoreceptors from retinal sections of both b-CD-treated and control C57BL/6 mice stained with Sudan
Black B (greyish blue) for lipids and phospholipids on photoreceptor outer segments. There were more lipids in the outer segments of control than in the b-CD-treated mice.
Mean ± SEM. n ¼ 8 for the b-CD-treated animals and n ¼ 5 for the untreated animals. RPE/BM e Retinal pigment epithelium/Bruch's membrane, IS - inner segment, OS e outer
segment. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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tribution of Ab on BM (Fig. 3A). C3 expressionwas also signiﬁcantly
reduced in the Cfh/ mice given the same high dosage pattern as
the C57BL/6 animals (Fig. 4B and D). However, reductions in C3
expression along BM of the short term treatment group were not
signiﬁcant (Fig. 4D). Hence, reducing dosage by 90% was effective in
reducing Ab but not C3. This may be because Ab is pro-
inﬂammatory and reductions in inﬂammation may lag behind Ab
removal.
4. Discussion
This study shows that 3 months topical treatment with b-CD has
a signiﬁcant impact on the aged mouse outer retina, reducing Ab
and C3 expression along with lowering lipid levels. This treatment
also increased RPE65 expression and improved retinal function in
aged mice. These results were reﬂected in treatment of Cfh/mice
where our aims were more limited, only targeting Ab and C3. b-CD
remained effective here evenwhen dosing was reduced by 90%, but
only in terms of Ab deposition. b-CD therapeutic abilities are
probably related to its hydrophobic internal structure and hydro-
philic outer surface, which increase the interaction and solubility of
materials such as lipids and Ab. CDs have been used previously with
success in Alzheimer mouse models and to clear Ab in the brain
(Yao et al., 2012) and in the retina to reduce lipofuscin (Nociari et al.,
2014), but in both studies administration has been systemic.
However, it is known that topical administration results in 60%
delivery to the retina, compared with only 40% when given sys-
temically (Sigurdsson et al., 2007). Hence, systemic delivery is an
inefﬁcient route that does not target selectively. In spite of this, CDs
have been used widely as vehicles for hydrophobic drug delivery.
They are safe, FDA approved and economic.In mice, Ab and C3 increase progressively with age on BM (Hoh
Kam et al., 2010. Catchpole et al., 2013) and this probably reduces
outer retinal perfusion and may increase hypoxia. The same is true
of lipid deposition. Lipid is a constituent of outer segments and it is
likely that this material accumulates with age as phagocytosis ef-
ﬁcacy probably declines.Whilewe show reductions in each of these
elements, our study is not the ﬁrst demonstration of the impact of
b-CD on deposition in the aged mouse outer retina. It has been
shown that b-CD delivered systemically also reduces lipofuscin that
accumulates with age (Nociari et al., 2014). Each of these deposited
materials eroded by b-CD have been implicated in AMD (Chen et al.,
2010; Neale et al., 2010; Curcio et al., 2011; Curcio et al., 2005a,
2005b; Curcio, et al., 2001).
Our results are similar to those obtained by Yao, J. et al. (Yao
et al., 2012) who used systemic b-CD delivery in an Alzheimer's
mouse model to reduce brain Ab deposition and microgliosis. The
mechanism by which cyclodextrins reduce Ab may be related to
their modulation of cellular cholesterol, which has a complex
relationship with amyloid precursor protein (APP) and Ab meta-
bolism (Grimm et al., 2007). APP and b- and g-secretases, which are
enzymes involved in Ab metabolism, are colocalised in cholesterol
rich lipid rafts. Hence, lowering cholesterol directly may affect APP
processing and reduce Ab production. Yao et al. (Yao et al., 2012)
have also shown that b-CD increases expression of genes critical for
lipid transportation, notably ABCA1 involved in increasing apoli-
poprotein E lipidation and improving Ab clearance (Hirsch-
Reinshagen et al., 2005).
b-CD treatment has a wider role than reducing deposition as it
signiﬁcantly improves retinal function and the visual cycle, both of
which decline with ageing. b-CD removes lipofuscin bisretinoids
that are by-products of the retinal pigmented epithelium resulting
from phagocytosing and these are toxic to RPE cells and as such
Fig. 3. ERG assessment of both scotopic and photopic responses in b-CD-treated and non-treated mice. Examples of evoked responses of a- and b-waves in A. scotopic and B.
photopic conditions of both groups. C. Graph shows that at higher luminance, there is marked increase of about 28% in the scotopic a-wave amplitude of the b-CD-treated mice
(P < 0.05) at 28.1 cd s/m2 compared to controls. D. Graph showing scotopic b-wave response. There is a 25% increase in the scotopic b-wave amplitude (P < 0.01 at 2.8 cd s/m2 and
P < 0.05 at 28.1 cd s/m2) of b-CD-treated mice compared to untreated group. E. Graph showing the photopic b-wave response of both groups. A signiﬁcant 20% improvement in the
photopic b-wave was seen in the b-CD-treated animals at the highest luminance, 84.2 (P < 0.05, Fig. 2C) as compared to the control group. Scotopic white light ﬂash stimuli;
3.5  106, 3.5  105, 3.5  104, 0.03, 0.3, 2.8 and 28.1 cd s/m2. Photopic responses to white light ﬂash stimuli were recorded with a background light of 20 cd/m2, to ﬂash stimuli
0.3, 2.8, 28.1 and 84.2 cd s/m2 were recorded. Mean ± SEM. n ¼ 10 for the b-CD-treated mice and n ¼ 5 for the untreated group for the ERG recordings.
J. Hoh Kam et al. / Experimental Eye Research 135 (2015) 59e6664impact on the visual cycle (Nociari et al., 2014). Hence, their
removal is likely to improve RPE cell function which is critical for
the cycle. But more importantly, Johnson et al. (Johnson et al., 2010)
revealed that b-CD efﬁciently removes all-trans retinol from frog
rod photoreceptors. During the visual cycle, 11-cis retinal chro-
mophore is photoisomerased into all-trans retinal, which is then
reduced to all-trans retinol in outer segments. When this accu-
mulates it is potentially toxic and this has been linked to Stargardt's
disease (Schutt et al., 2000; Sparrow and Cai, 2001). In the frog, b-
CD facilitates removal of this material and hence improves regen-
eration of 11-cis isomers. This may potentially explain the elevated
RPE65 expression in b-CD-treated aged animals, as RPE65 is
involved in the conversion of all-trans retinol to 11-cis retinal
during phototransduction.
Given the improved visual cycle and reductions in Ab and
inﬂammation it is not surprising that the ERG improved. However,
ERGs are relatively insensitive and signiﬁcant changes in amplitude
of the respective waves require disproportionately large changes in
underlying biology before they are reliably detected. An example of
this insensitivity comes from the ﬁnding that ERG thresholds are
2e3 log units less sensitive than those based on psychophysical
measures (Ruseckaite et al., 2011). Hence, the true impact of b-CDon improved psychophysical visual function may be more signiﬁ-
cant than reported here.
Our improved ERGs were largely conﬁned to higher luminance.
There may be many reasons for this including differential satura-
tion. However, recently it has been shown that age-related cone
loss in mice occurs before rod loss. It is present within the ﬁrst year
of life while rod loss is primarily a feature of the second year (Cunea
et al., 2014). Hence, as our animals were around a year of age when
sacriﬁced, cones may have been in a more vulnerable state than
rods. Further, there is a growing clinical evidence that cones may be
particularly vulnerable to inﬂammation (see discussion in Cunea
et al., 2014) and hence may have improved function follow CD
treatment. However we do not have proof for this as an explanation
and the speciﬁc underlying mechanism has yet to be revealed.
There are two additional reasons to think that b-CD may have
potential in dealing with problems related to retinal ageing. First,
we show that b-CD is effective in aged Cfh/ mice. These are
regarded as an AMDmodel as they have similar genotype to 50% of
AMD patients (Edwards et al., 2005; Haines et al., 2005) and suffer
excess Ab deposition and inﬂammation in the outer retina
(Catchpole et al., 2013; Hoh Kam et al., 2013) that is associated with
advanced photoreceptor loss (Hoh Kam et al., 2013). Second, we
Fig. 4. b-CD treatment efﬁciently removes Ab and complement C3 along the RPE/BM interface of Cfh/mice. A. Representative micrographs of retinal sections of Cfh/mice from
all three groups immunostained with Ab (red) and counterstained with DAPI (blue). Ab is heavily expressed in controls compared to either the short treatment b-CD ST-treated mice
or long treatment b-CD LT-treated mice. B. Representative micrographs of retinal sections of Cfh/ mice from all three groups immunostained with C3 (green) and counterstained
with DAPI (blue). The control group expressed more C3 than the two other b-CD-treated groups. C. Graph showing that the b-CD-treated groups have signiﬁcantly lower expression
of Ab along the RPE/BM interface than the control group. (P < 0.01 for b-CD ST and P < 0.001 for the b-CD LT when compare to the control group). D. Graph showing the level of C3
expression the all three groups. The control group has a signiﬁcantly higher expression of C3 compared to the b-CD LT group (P < 0.01) but not signiﬁcantly different from the b-CD
ST-treated mice. Mean ± SEM. n ¼ 5 for the b-CD ST treated Cfh/, n ¼ 10 for the b-CD LT-treated Cfh/ mice and n ¼ 5 for the untreated animals. RPE/BM e Retinal pigment
epithelium/Bruch's membrane. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
J. Hoh Kam et al. / Experimental Eye Research 135 (2015) 59e66 65show that signiﬁcant reductions in Ab deposition in the outer retina
of these mice can be obtained with dosing at only approximately
10% of the level undertaken in the C57BL/6 mice used more
extensively here. While we did reveal signiﬁcant reductions in Ab,
our inability to show a signiﬁcant reduction in inﬂammation with
this low dosing may be due to time. Had the treatment been
extended it is possible that inﬂammation would have declined in
response to reduced pro-inﬂammatory Ab.
A number of studies have shown reductions in retinal Ab and
inﬂammation with systemic immunotherapies in mice as a poten-
tial route to an AMD therapy. A key study has also shown improved
ERG b-wave function in transgenic mice. However, some models
are relatively complex and systemic immunotherapies are inher-
ently problematic (Bowes Rickman et al., 2013; Ding et al., 2011). b-
CD has been used extensively in humans for many years (Loftsson
and Duchene, 2007). Our results imply that the effects in their
use may be down to multiple factors. These include drugs that they
carry and also what CD might do once they have deposited such
drugs. Hence CDs may not be a reliable vehicle alone without such
qualiﬁcations.
Given the data presented here using topical administration it is
possible that it could be used in AMD patients. While there are very
considerable retinal differences between mice and human that
raise serious questions about the validity of the mouse model, this
has to be balanced against other key issues. These include the lack
of a realistic alternative, the pressing nature of the disease and the
safe and economic route that b-CD offers.Acknowledgement
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